Take a look behind the scenes of a recent Future Virology review as we ask author Geoffrey Dusheiko about the challenges facing hepatitis B and what the future may hold in terms of functional cure and new research directions.
After completing a strategic review, Allergan plans to sell its women’s health and infectious disease businesses, to focus on its four core areas of aesthetics, central nervous system diseases, eye care and gastrointestinal conditions.
Glenn Tillotson tells us about the interesting and rewarding opportunities young scientists could have in the pharmaceutical industry, highlighting how his own perceptions have changed over time.
The US FDA and the European Medicines Agency are investigating reports of neural tube defects in babies born to women on GlaxoSmithKline’s antiretroviral drug dolutegravir.
In our latest interview, we spoke to Jean-Pierre Paccaud, Director of Business Development & Corporate Strategy at GARDP, about the drug developer’s model and his thoughts on the wider field.
A new gene identified in P. aeruginosa could act as a prognostic biomarker and treatment target for patients with bloodstream infections.
E. coli’s internal bomb – the toxin-antitoxin system – could be triggered to make bacteria turn on themselves, offering a new target for antimicrobial approaches in drug design.
Our sister site, MedChemNet, spoke to Joseph Hargan-Calvopiña, Program Manager at BIO Ventures for Global Health, to find out more about their work in global drug development for neglected tropical diseases.
We recently spoke about the ins and outs of funding and financing for antimicrobials with John Rex, who shares his thoughts on the issues underlying antibiotic development, the recent DRIVE-AB report, and where we might be 10 years in the future.
We look at some of the highlights of our Twitter chat (#TalkTB), where we questioned Madhukar Pai, Nandita Venkatesan and Jacob Creswell about all things tuberculosis – from diagnosis to social stigma.
